Measuring the impact of antimicrobial stewardship programs

Expert Review of Anti-Infective Therapy

Volumn 14, Issue 6, 2016, Pages 569-575

  Dik, Jan Willem H ^a   Hendrix, Ron ^a,b   Poelman, Randy ^a   Niesters, Hubert G ^a   Postma, Maarten J ^a,c   Sinha, Bhanu ^a   Friedrich, Alexander W ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b Department of Medical Microbiology   (Netherlands)

^c UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

A teams; antimicrobial resistance; Antimicrobial stewardship; expert review; one health

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ANTIMICROBIAL STEWARDSHIP PROGRAM; COST BENEFIT ANALYSIS; DIAGNOSTIC TEST; EDUCATION PROGRAM; HEALTH CARE QUALITY; HOSPITAL READMISSION; HUMAN; INFECTION CONTROL; INFECTION PREVENTION; INFECTION RATE; LENGTH OF STAY; MORTALITY RATE; PATIENT CARE; PATIENT SAFETY; PERSONALIZED MEDICINE; POINT OF CARE TESTING; RECURRENCE RISK; REVIEW; COMMUNICABLE DISEASES; DRUG UTILIZATION REVIEW; METHODOLOGY; MICROBIOLOGY; ORGANIZATION AND MANAGEMENT; PROGRAM EVALUATION; STANDARDS; TREATMENT OUTCOME;

ANTI-INFECTIVE AGENTS; COMMUNICABLE DISEASES; DRUG RESISTANCE, MICROBIAL; DRUG UTILIZATION REVIEW; HUMANS; PROGRAM EVALUATION; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 84965035987     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1080/14787210.2016.1178064     Document Type: Review

References (60)

1. H.Goossens Antibiotic consumption and link to resistance. Clin Microbiol Infect. 2009;15(Suppl 3):12–15.
2. B.M.Marshall, S.B.Levy. Food animals and antimicrobials: impacts on human health. Clin Microbiol Rev. 2011;24:718–733.
3. M.J.Renwick, V.Simpkin, E.Mossialos. International and European initiatives targeting innovation in antibiotic drug discovery and development. The need of a one health – one Europe – one world framework. Den Haag, Netherlands: Dutch Ministry of Health; 2016. p. 1–93.
4. World Health Organization. The evolving threat of antimicrobial resistance – options for action. Geneva, Switzerland; 2012; [cited 2016 Feb22]. Available from: http://apps.who.int/iris/bitstream/10665/44812/1/9789241503181_eng.pdf
5. T.Dellit, R.Owens, J.McGowan, et al. Infectious diseases society of America and the society for healthcare epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis. 2007;44:159–177.
6. K.With de, F.Allerberger, S.Amann, et al. S3-Leitlinie. S3-Guideline: strategies to enhance rational use of antibiotics in hospital. Infection. 2016. doi:10.1007/s15010-016-0885-z. [Epub ahead of print]
7. SWAB. De kwaliteit van het antibioticabeleid in Nederland; 2012; [cited 2016 Feb22]. Available from: http://www.swab.nl/swab/cms3.nsf/uploads/5FD2BE2700E8B433C1257A680028D9F0/$FILE/visiedoc%20SWAB%20vs%2021%20junifinal.pdf
8. P.Davey, E.Brown, E.Charani, et al. Interventions to improve antibiotic prescribing practices for hospital inpatients. Cochrane Database Syst Rev. 2013;4:CD003543.
9. E.C.Schuts, M.E.J.L.Hulscher, J.W.Mouton, et al. A systematic review and meta-analysis of current evidence on hospital Antimicrobial Stewardship objectives. Lancet Infect Dis. 2016. pii:S1473-3099(16)00065-7. doi:10.1016/S1473-3099(16)00065-7. [Epub ahead of print]•• Highly extensive systematic review and meta-analysis, giving a complete overview on the effects of ASPs.
10. J.McGowan. Antimicrobial stewardship–the state of the art in 2011: focus on outcome and methods. Infect Control Hospital Epidemiol. 2012;33:331–337.
11. A.M.Morris. Antimicrobial stewardship programs: appropriate measures and metrics to study their impact. Curr Treat Options Infect Dis. 2014;6:101–112.
12. S.R.Evans, D.Rubin, D.Follmann, et al. Desirability of outcome ranking (DOOR) and response adjusted for duration of antibiotic risk (RADAR). Clin Infect Dis. 2015;61:800–806.
13. J.E.McGowan, D.N.Gerding. Does antibiotic restriction prevent resistance? New Horiz. 1996;4:370–376.
14. P.Howard, C.Pulcini, G.Levy Hara, et al. An international cross-sectional survey of antimicrobial stewardship programmes in hospitals. J Antimicrob Chemother. 2015;70:1245–1255.
15. S.L.Lammie, J.M.Hughes. Antimicrobial resistance, food safety, and one health: the need for convergence. Ann Rev Food Sci Technol. 2016;7:287–312.
16. J.H.Dik, R.Poelman, A.W.Friedrich, et al. An integrated stewardship model: antimicrobial, infection prevention and diagnostic (AID). Future Microbiol. 2016;11:93–102.
17. T.Donker, J.Wallinga, H.Grundmann. Patient referral patterns and the spread of hospital-acquired infections through national health care networks. PLoS Comput Biol. 2010;6(3):e1000715.
18. M.Ciccolini, T.Donker, R.R.Köck, et al. Infection prevention in a connected world: the case for a regional approach. Int J Med Microbiol. 2013;303:380–387.
19. J.Müller, A.Voss, R.Köck, et al. Cross-border comparison of the Dutch and German guidelines on multidrug-resistant gram-negative microorganisms. Antimicrob Resist Infect Control. 2015;4:7.
20. A.M.Caliendo, D.N.Gilbert, C.C.Ginocchio, et al. Better tests, better care: improved diagnostics for infectious diseases. Clin Infect Dis. 2013;57(Suppl 3):S139S170.
21. S.S.Buehler, B.Madison, S.R.Snyder, et al. Effectiveness of practices to increase timeliness of providing targeted therapy for inpatients with bloodstream infections: a laboratory medicine best practices systematic review and meta-analysis. Clin Microbiol Rev. 2016;29:59–103.
22. B.B.Rogers, P.Shankar, R.C.Jerris, et al. Impact of a rapid respiratory panel test on patient outcomes. Arch Pathol Lab Med. 2015;139:636–641.
23. E.Tacconelli, G.De Angelis, C.de Waure, et al. Rapid screening tests for meticillin-resistant Staphylococcus aureus at hospital admission: systematic review and meta-analysis. Lancet Infect Dis. 2009;9(9):546–554.
24. M.Wassenberg, J.Kluytmans, S.Erdkamp, et al. Costs and benefits of rapid screening of methicillin-resistant Staphylococcus aureus carriage in intensive care units: a prospective multicenter study. Crit Care. 2012;16(1):R22.
25. C.A.Mather, B.J.Werth, S.Sivagnanam, et al. Rapid detection of vancomycin-intermediate Staphylococcus aureus by matrix-assisted laser desorption ionization-time of flight mass spectrometry. J Clin Microbiol. 2016;54(4):883–890.
26. S.R.Evans, A.M.Hujer, H.Jiang, et al. Rapid molecular diagnostics, antibiotic treatment decisions, and developing approaches to inform empiric therapy: PRIMERS I and II. Clin Infect Dis. 2016;62:181–189.
27. K.A.Bauer, J.E.West, J.M.Balada-Llasat, et al. An antimicrobial stewardship program’s impact with rapid polymerase chain reaction methicillin-resistant Staphylococcus aureus/S. Aureus blood culture test in patients with S. aureus bacteremia. Clin Infect Dis. 2010;51(9):1074–1080.
28. O.Clerc, G.Prod’hom, L.Senn, et al. Matrix-assisted laser desorption ionization time-of-flight mass spectrometry and PCR-based rapid diagnosis of Staphylococcus aureus bacteraemia. Clin Microbiol Infect. 2014;20(4):355–360.
29. R.Banerjee, C.B.Teng, S.A.Cunningham, et al. Randomized trial of rapid multiplex polymerase chain reaction-based blood culture identification and susceptibility testing. Clin Infect Dis. 2015;61(7):1071–1080.
30. V.Nobre, S.Harbarth, J.D.Graf, et al. Use of procalcitonin to shorten antibiotic treatment duration in septic patients: a randomized trial. Am J Resp Crit Care Med. 2009;177(5):498–505.
31. L.Bouadma, C.E.Luyt, F.Tubach, et al. Use of procalcitonin to reduce patients’ exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet. 2010;375(9713):463–474.
32. P.Schuetz, B.Müller, M.Christ-Crain, et al. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. Cochrane Database Syst Rev. 2012;9:CD007498.
33. E.de Jong, J.A.van Oers, A.Beishuizen, et al. Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trial. Lancet Infect Dis. 2016. pii:S1473-3099(16)00053-0. doi:10.1016/S1473-3099(16)00053-0. [Epub ahead of print]
34. E.B.Popowitch, S.S.O’Neill, M.B.Miller. Comparison of the Biofire FilmArray RP, Genmark eSensor RVP, Luminex xTAG RVPv1, and Luminex xTAG RVP fast multiplex assays for detection of respiratory viruses. J Clin Microbiol. 2013;51(5):1528–1533.
35. N.L.Plantinga, M.J.Bonten. Selective decontamination and antibiotic resistance in ICUs. Crit Care. 2015;19:259.
36. N.Daneman, S.Sarwar, R.A.Fowler, et al.; SuDDICU Canadian Study Group. Effect of selective decontamination on antimicrobial resistance in intensive care units: a systematic review and meta-analysis. Lancet Infect Dis. 2013;13:328–341.
37. J.H.Dik, P.Vemer, A.W.Friedrich, et al. Financial evaluations of antibiotic stewardship programs – a systematic review. Front Microbiol. 2015;6:317.
38. S.Coulter, K.Merollini, J.A.Roberts, et al. The need for cost-effectiveness analyses of antimicrobial stewardship programmes: a structured review. Int J Antimicrob Agents. 2015;46:140–149.
39. P.Lesprit, C.Landelle, C.Brun-Buisson. Clinical impact of unsolicited post-prescription antibiotic review in surgical and medical wards: a randomized controlled trial. Clin Microbiol Infect. 2013;19:91–97.
40. E.Fleet, G.Gopal Rao, B.Patel, et al. Impact of implementation of a novel antimicrobial stewardship tool on antibiotic use in nursing homes: a prospective cluster randomized control pilot study. J Antimicrob Chemother. 2014;69:2265–2273.
41. M.F.Drummond, M.J.Sculpher, G.W.Torrance, et al. Cost analysis. In: M.F.Drummond, editor. Methords for the economic evaluation of health care programmes. 3rd ed. Oxford: Oxford University Press; 2005. p. 65–101.• Must-read when doing an economic evaluation of a healthcare program.
42. D.Nathwani, J.Sneddon, A.Patton, et al. Antimicrobial stewardship in Scotland: impact of a national programme. Antimicrob Resist Infect Control. 2012;1(1):7.
43. C.Slimings, T.V.Riley. Antibiotics and hospital-acquired Clostridium difficile infection: update of systematic review and meta-analysis. J Antimicrob Chemother. 2014;69:881–891.
44. L.T.Schulz, B.C.Fox, R.E.Polk. Can the antibiogram be used to assess microbiologic outcomes after antimicrobial stewardship interventions? A critical review of the literature. Pharmacotherapy. 2012;32:668–676.
45. T.Donker, M.Ciccolini, J.Wallinga, et al. [Analysis of patient flows: basis for regional control of antibiotic resistance]. Ned Tijdschr Geneeskd. 2015;159:A8468. Dutch.
46. E.Tacconelli, M.A.Cataldo, M.Paul, et al. STROBE-AMS: recommendations to optimise reporting of epidemiological studies on antimicrobial resistance and informing improvement in antimicrobial stewardship. BMJ Open. 2016;6:e010134.• Providing a much needed set of recommendations on the reporting of antimicrobial resistance studies.
47. Health Council of the Netherlands. Antibiotics in hospitals: prophylaxix and antibiotic stewardship. Vol. 12. The Hague, Netherlands: Health Council of the Netherlands; 2015. p. 1–64; [cited 2016 Apr5]. Available from: https://www.gezondheidsraad.nl/sites/default/files/201512_antibiotica_in_ziekenhuizen.pdf
48. D.Nathwani, W.Lawson, M.Dryden, et al. Implementing criteria-based early switch/early discharge programmes: a European perspective. Clin Microbiol Infect. 2015;21:47–55.
49. C.Tan, M.Ritchie, J.Alldred, et al. Validating hospital antibiotic purchasing data as a metric of inpatient antibiotic use. J Antimicrob Chemother. 2016;71:547–553.
50. K.De With, H.Bestehorn, M.Steib Bauert, et al. Comparison of defined versus recommended versus prescribed daily doses for measuring hospital antibiotic consumption. Infection. 2009;37:349–352.
51. E.Fortin, P.S.Fontela, A.R.Manges, et al. Measuring antimicrobial use in hospitalized patients: a systematic review of available measures applicable to paediatrics. J Antimicrob Chemother. 2014;69(6):1447–1456.
52. C.Gagliotti, E.Ricchizzi, R.Buttazzi, et al. Hospital statistics for antibiotics: defined versus prescribed daily dose. Infection. 2014;42:869–873.
53. R.E.Polk, C.Fox, A.Mahoney, et al. Measurement of adult antibacterial drug use in 130 US hospitals: comparison of defined daily dose and days of therapy. Clin Infect Dis. 2007;44:664–670.
54. D.D.DePestel, E.H.Eiland3rd, K.Lusardi, et al. Assessing appropriateness of antimicrobial therapy: in the eye of the interpreter. Clin Infect Dis. 2014;59(Suppl 3):S154S161.
55. V.Spoorenberg, M.E.J.L.Hulscher, R.Akkermans, et al. Appropriate antibiotic use for patients with urinary tract infections reduces length of hospital stay. Clin Infect Dis. 2014;58:164–169.• Nicely performed study, looking at appropriateness on a patient level and relating it to LOS reductions.
56. A.J.Stewardson, S.Harbarth, N.Graves; TIMBER Study Group. Valuation of hospital bed-days released by infection control programs: a comparison of methods. Infect Control Hosp Epidemiol. 2014;35(10):1294–1297.
57. R.J.Brüggemann, R.E.Aarnoutse. Fundament and prerequisites for the application of an antifungal TDM service. Curr Fungal Infect Rep. 2015;9:122–129.
58. M.Valerio, P.Muñoz, C.G.Rodriguez, et al. Antifungal stewardship in a tertiary-care institution: a bedside intervention. Clin Microbiol Infect. 2015;21:1–9.
59. P.Muñoz, M.Valerio, A.Vena, et al. Antifungal stewardship in daily practice and health economic implications. Mycoses. 2015;58:14–25.
60. M.van Limburg, B.Sinha, J.R.Lo-Ten-Foe, et al. Evaluation of early implementations of antibiotic stewardship program initiatives in nine Dutch hospitals. Antimicrob Res Infect Control. 2014;3:33.